New Obesity, Fitness and Wellness Study Findings Reported from Georgetown University (A Comparison of Us Individual and Family Plan Medication Coverage for Overactive Bladder): Obesity, Fitness and Wellness

2024 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity Daily News -- Research findings on Obesity, Fitness and Wellness are discussed in a new report. According to news reporting from Washington, District of Columbia, by NewsRx journalists, research stated, “Importance There is strong evidence for long-term cognitive effects with anticholinergic use. Differences in insurance coverage of anticholinergics and beta-3 agonists hinder individualization of overactive bladder (OAB) treatment.”

The news correspondents obtained a quote from the research from Georgetown University, “The aims of the study were to assess individual and family health insurance plan coverage for select OAB medications and to compare coverage of preferred medications to those with a greater risk of cognitive dysfunction. This cross-sectional study analyzed formularies for the top 7 U.S. medical insurers. Coverage tiers were assessed for the following 7 OAB medications: (1) oxybutynin instant-release 5 mg, (2) oxybutynin extended-release 5 mg, (3) solifenacin 5 mg, (4) trospium instant-release 20 mg, (5) trospium extended-release 60 mg, (6) mirabegron 25 mg, and (7) vibegron 75 mg. Coverage was compared between nonpreferred (oxybutynin, solifenacin) and preferred medications (trospium, mirabegron, vibegron). Coverage scores, representing a weighted average based on coverage tier frequency relative to the number of plans investigated for each state or insurer, were generated with a lower coverage score indicating better coverage (range, 0.2-1.0). A total of 2,780 insurance plans from 41 states representing a 47% market share for the individual and family marketplace were evaluated. Oxybutynin IR had the best coverage score across insurers (0.2) while vibegron had the worst (0.92). Preferred medications were more often designated to higher tiers with worse coverage compared with nonpreferred medications (P < 0.001). Less concordance in coverage between insurers was noted for anticholinergics with greater bladder specificity and for extended-release formulations.”

According to the news reporters, the research concluded: “Despite risks with anticholinergics, beta-3 agonists were more expensive across all insurers highlighting the need for expanded coverage of preferred medications to avoid cognitive dysfunction when undergoing treatment for OAB.”

This research has been peer-reviewed.

For more information on this research see: A Comparison of Us Individual and Family Plan Medication Coverage for Overactive Bladder. Urogynecology, 2024;30(3):214-222. Urogynecology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

Our news journalists report that additional information may be obtained by contacting Neha G. Gaddam, Georgetown University, MedStar Washington Hospital Center, Washington, DC 20057, United States. Additional authors for this research include Megan B. Wallace and Alexis A. Dieter.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/spv.0000000000001453. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)